检索结果-南通市图书馆

Expert consensus on radiotherapy combined with immunotherapy for esophageal cancer(2024 edition)

Radiation Medicine and Protection 2024年第2期5卷 59-67页

作者： Professional Committee of Radiation Oncology China Anti-Cancer Association Branch of Radiation Oncology Chinese Medical Association Branch of Radiation Oncology TreatmentPhysician Chinese Medical Doctor Association qingsong pang Jun Wang Zhouguang Hui Wencheng Zhang 不详 Tianjin Medical University Cancer Institute&Hospital Tianjin 300060China the Fourth Hospital of Hebei Medical University Shijiazhuang 050011China National Cancer Center National Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Tianjin Medical University Cancer Hospital China

Radiotherapy represents an essential treatment approach for esophageal *** recent years,immunotherapy combined with chemotherapy has become the first-line standard treatment for patients with advanced esophageal *** phase III studies on immunotherapy combined with radiotherapy for locally advanced esophageal cancer are currently *** evidence-based medical data are urgently needed to support the integration of immunotherapy and chemoradiotherapy as a new treatment strategy for patients with locally advanced esophageal *** consensus,formulated based on the latest study results,in-depth research,and thorough discussions,provides a comprehensive set of *** document extensively covers treatment strategies and evaluation methods for radiotherapy combined with immunotherapy across patients with operable esophageal cancer,inoperable locally advanced esophageal cancer,and advanced esophageal ***,common complications and radiation-related issues associated with radiotherapy combined with immunotherapy are discussed,serving as clinical *** expert group comprised members from the Professional Committee of Radiation Oncology,China Anti-Cancer Association,the Branch of Radiation Oncology,Chinese Medical Association,and the Branch of Radiation Oncology Treatment Physician,Chinese Medical Doctor Association.

关键词： Esophageal squamous cell carcinoma Esophageal adenocarcinoma Immunotherapy Chemoradiotherapy Radiotherapy Expert consensus

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

放疗在胸腺肿瘤治疗中的应用与研究进展

引用

中华放射医学与防护杂志 2024年第4期44卷 337-344页

作者：胡昕阳卢喜科于振涛庞青松天津医科大学肿瘤医院放疗科国家恶性肿瘤临床医学研究中心天津市恶性肿瘤临床医学研究中心天津市肿瘤防治重点实验室天津300060 天津市胸科医院胸外科天津300050 中国医学科学院肿瘤医院深圳医院胸外科深圳518117

胸腺肿瘤是一种罕见的纵隔肿瘤,放疗是治疗胸腺肿瘤的重要手段之一,目前放疗在不同分期胸腺瘤之中的具体应用仍有诸多争议。本文综述术后/根治性放疗在不同分期胸腺肿瘤治疗中的应用、病理分型与预后的关系以及目前免疫治疗在胸腺肿瘤... 详细信息

胸腺肿瘤是一种罕见的纵隔肿瘤,放疗是治疗胸腺肿瘤的重要手段之一,目前放疗在不同分期胸腺瘤之中的具体应用仍有诸多争议。本文综述术后/根治性放疗在不同分期胸腺肿瘤治疗中的应用、病理分型与预后的关系以及目前免疫治疗在胸腺肿瘤中的研究进展,旨在为临床诊疗和后续研究提供参考。

关键词：胸腺肿瘤放射治疗预后

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Brain metastasis in non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations： a report of seven cases and literature review

引用

Cancer Biology & Medicine 2017年第4期14卷 418-425页

作者： Puchun Er Tian Zhang Jing Wang qingsong pang Ping Wang Department of Radiotherapy Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin Tianjin's Clinical Research Center for Cancer Tianjin 300060 China

Brain metastasis(BM)arising from non-small cell lung cancer(NSCLC)with rare epidermal growth factor receptor(EGFR)mutations is quite *** prognosis and therapeutic effects of BM remain *** the best of our knowledge,this is the first report to make a separate analysis of BM from NSCLC patients with original uncommon EGFR *** retrospectively reviewed 7 cases of BM arising from 42 cases of uncommon EGFR mutated lung cancer in Tianjin Medical University Cancer Institute and *** also performed a literature review to assess therapeutic features and outcomes.

关键词： Brain metastasis NSCLC uncommon EGFR mutations EGFR-TKIs brain radiotherapy chemotherapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma:A randomized,multicenter,phase Ⅲ clinical trial

引用

Cancer Communications 2024年第10期44卷 1173-1188页

作者： Jian Zhang Minghao Li Kaixian Zhang Anping Zheng Guang Li Wei Huang Shaoshui Chen Xiangming Chen Xiaomin Li Yanxing Sheng Xinchen Sun Liping Liu Xiaowei Liu Jie Li Jun Wang Hong Ge Shucheng Ye qingsong pang Xianwen Zhang Shengbin Dai Richard Yu Wendong Gu Mingming Dai Gaowa Siqin Yunwei Han Xiaolin Ge Xin Yuan Yongjing Yang Haiwen Zhu Juan Pu Lihua Dong Xiangdong Sun Jundong Zhou Weidong Mao Fei Gao Haiqun Lin Heyi Gong Tao Zhou Zhenjiang Li Hongsheng Li Zhongtang Wang Baosheng Li Department of Oncology Central Hospital Affiliated to Shandong First Medical UniversityJinanShandongP.R.China Department of Radiation Oncology Shandong Cancer Hospital and InstituteShandong First Medical University and Shandong Academy of Medical SciencesJinanShandongP.R.China Department of Oncology Tengzhou Central People’s HospitalTengzhouShandongP.R.China Department of Radiation Oncology Anyang Tumor HospitalAnyangHenanP.R.China Department of Radiation Oncology the First Hospital of China Medical UniversityShenyangLiaoningP.R.China Department of Oncology Binzhou Medical University HospitalBinzhouShandongP.R.China Department of Oncology Taian CentralHospitalTaianShandongP.R.China Department of Radiation Oncology Shanxi Province Cancer HospitalTaiyuanShanxiP.R.China Department of Oncology Liaocheng People’s HospitalLiaochengShandongP.R.China Department of Radiation Oncology the First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuP.R.China Department of Oncology Jining First People′s HospitalJiningShandongP.R.China Department of Oncology the Affiliated Hospital of Jining Medical UniversityJiningShandongP.R.China Department of Radiation Oncology the Fourth Hospital of Hebei Medical UniversityHebei Clinical Research Center for Radiation OncologyShijiazhuangHebeiP.R.China Department of Radiation Oncology the Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhouHenanP.R.China Department of Radiation Oncology Tianjin Medical University Cancer Institute and HospitalNational Clinical Research Center for CancerKey Laboratory ofCancer Prevention and TherapyTianjin’s ClinicalResearch Center for CancerTianjinP.R.China Department of Oncology Subei People’s Hospital of Jiangsu ProvinceYangzhouJiangsuP.R.China Department of Oncology Taizhou People’s Hospital of Jiangsu ProvinceTaizhouZhejiangP.R.China Department of Radiation Oncology the Affiliated Hospital of Inner Mongolia Medical UniversityHohhotInner MongoliaP.R.China Department of Radiation O

Background:Concurrent chemoradiotherapy(CCRT)is the standard treatment for locally advanced esophageal squamous cell carcinoma(ESCC).However,the optimal radiotherapy regimen,particularly in terms of total dose and planned range of irradiation field,remains *** phase III clinical trial aimed to compare the survival benefits between different radiation doses and different target ***:This trial compared two aspects of radiation treatment,total dose and field,using a two-by-two factorial *** high-dose(HD)group received 59.4 Gy radiation,and the standard-dose(SD)group received 50.4 *** involved field irradiation(IFI)group and elective nodal irradiation(ENI)group adopted different irradiation *** participants were assigned to one of the four groups(HD+ENI,HD+IFI,SD+ENI and SD+IFI).The primary endpoint was overall survival(OS),and the secondary endpoints included progressionfree survival(PFS).The synergy indexwas used to measure the interaction effect between dose and ***:The interaction analysis did not reveal significant synergistic effects between the dose and irradiation *** comparison to the target field,patients in IFI or ENI showed similar OS(hazard ratio[HR]=0.99,95%CI:0.80-1.23,p=0.930)and PFS(HR=1.02,95%CI:0.82–1.25).TheHDtreatment did not show significantly prolonged OS compared with SD(HR=0.90,95%CI:0.72–1.11,p=0.318),but it suggested improved PFS(25.2 months to 18.0 months).Among the four groups,the HD+IFI group presented the best survival,while the SD+IFI group had the worst *** significant difference in the occurrence of severe adverse events was found in dose or field ***:IFI demonstrated similar treatment efficacy to ENI in CCRT of *** HD demonstrated improved PFS,but did not significantly improve *** dose escalation based on IFI(HD+IFI)showed better therapeutic efficacy than the current recommendation(SD+ENI)and is worth further validation.

关键词： clinical trial concurrent chemoradiotherapy elective nodal radiation esophageal squamous cell carcinoma high dose radiation involved field radiation overall survival standard dose radiation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

局部晚期食管鳞癌新辅助放化疗疗效的影响因素及预测

引用

中华放射肿瘤学杂志 2024年第5期33卷 413-418页

作者：尔璞醇赵芳冬李嘉诚陈曦董杰张天章文成王平庞青松天津医科大学总医院放射治疗科天津300052 天津医科大学肿瘤医院放射治疗科国家恶性肿瘤临床医学研究中心天津市恶性肿瘤临床医学研究中心天津市肿瘤防治重点实验室天津300060 天津医科大学肿瘤医院营养科天津300060

目的探讨经新辅助放化疗(NCRT)的局部晚期食管鳞癌(ESCC)患者行根治性切除术后达到病理完全缓解(pCR)的影响因素,比较NCRT(40 Gy分20次)后达到pCR与否的两组ESCC患者的临床疗效及预后。方法在一项前瞻性临床试验所收集的患者中,选取2015... 详细信息

目的探讨经新辅助放化疗(NCRT)的局部晚期食管鳞癌(ESCC)患者行根治性切除术后达到病理完全缓解(pCR)的影响因素,比较NCRT(40 Gy分20次)后达到pCR与否的两组ESCC患者的临床疗效及预后。方法在一项前瞻性临床试验所收集的患者中,选取2015年6月至2019年10月于天津医科大学肿瘤医院经NCRT后行根治切除术的87例ESCC患者。将上述患者分为术后pCR组(35例)和非pCR组(52例),回顾其临床病理特征并完善后期随访,运用Kaplan-Meier及Cox回归等方法对两组患者的生存预后及影响因素进行比较。结果经NCRT后,有40%的手术患者达到pCR。单因素分析显示,术后pCR组和非pCR组患者的无瘤生存(DFS)期(39.3∶14.1个月,P<0.01)、总生存(OS)期(64.0∶25.2个月,P<0.05)的差异均有统计学意义。多因素分析显示,术后pCR情况、患者的年龄分组、原发多病灶与否、放化疗后的疗效评价情况及术后病理结果均为影响患者生存预后的重要因素,两组差异均有统计学意义(P<0.05)。结论ESCC经NCRT后pCR状况和患者的生存预后密切相关,且术后pCR具有预测ESCC患者长期生存临床预后的重要价值。

关键词：食管鳞状细胞癌新辅助放化疗法病理完全缓解临床预后

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Evaluation of the Curative Effect of External Beam Radiotherapy and Brachytherapy for Tongue Carcinoma

引用

Chinese Journal of Clinical Oncology 2007年第3期4卷 201-204页

作者： Ping Wang qingsong pang Radiotherapy Department of Tianjin Cancer Hospital Tianjin Medical University Tianjin 300060 China.

OBJECTIVE To evaluate the curative effect of external beam radiothera-py (EBRT) and brachytherapy (BT) for tongue carcinoma. METHODS From 1991 to 2003, 35 patients received EBRT and BT in our department. We analyzed their curative and side effects retrospectively. RESULTS Local control was 80%. The 3-year overall (OS) and disease specific survival (DSS) rates were 75% and 79%. One patient developed metastases. Three patients (9%) developed different late complications. CONCLUSIONS Local regional control, survival, and complications in patients with tongue carcinoma treated by EBRT and BT have been satis-factory.

关键词： tongue carcinoma brachytherapy local control survival.

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

NS1-binding protein radiosensitizes esophageal squamous cell carcinoma by transcriptionally suppressing c-Myc

引用

Cancer Communications 2018年第1期38卷 352-365页

作者： Yuwen Wang Jingjing Cheng Dan Xie Xiaofeng Ding Hailing Hou Xi Chen Puchun Er Furong Zhang Lujun Zhao Zhiyong Yuan qingsong pang Ping Wang Dong Qian Department of Radiotherapy Tianjin Medical University Cancer Institute and HospitalTianjin 300060P.R.China National Clinical Research Center for Cancer Tianjin Medical University Cancer Institute and HospitalTianjin 300060P.R.China Key Laboratory of Cancer Prevention and Therapy TianjinTianjin’s Clinical Research Center for CancerHuanhu West StreetTianjin 300060P.R.China State Key Laboratory of Oncology in South China Guangzhou 510060GuangdongP.R.China Sun Yat-sen University Cancer Center Guangzhou 510060GuangdongP.R.China

Background:Cisplatin-based chemotherapy with concurrent radiotherapy is a standard treatment for advanced esophageal squamous cell carcinoma(ESCC).NS1-binding protein(NS1-BP),a member of the BTB-kelch protein fam-ily,has been shown to inhibit the proliferation of Hela cells by suppressing *** the present study,we examined the potential function role of NS1-BP expression in ESCC,and particularly,the sensitivity of ESCC to ***:NS1-BP expression was examined using immunohistochemistry in two cohorts(n=98 for the training cohort;n=46 for independent validation cohort)of ESCC patients receiving cisplatin-based chemotherapy and con-current *** esophageal mucosal tissue blocks were used as a *** also conducted a series of in vitro and in vivo experiments to examine the potential effects of over-expressing NS1-BP on ESCC cells,and particu-larly their sensitivity to ionizing ***:In the training cohort,NS1-BP downregulation was observed in 59%(85/144)of the ESCC ***1-BP downregulation was associated with chemoradiotherapeutic resistance and shorter disease-specific survival(DSS)in both the training and validation ***-expressing NS1-BP in cultured ESCC cells substantially increased the cellular response to irradiation both in vitro and in ***1-BP also significantly enhanced IR-induced apoptosis,and abrogated IR-induced G2/M cell-cycle arrest and ATM/Chk1 *** assays indicated that NS1-BP could interact with c-Myc promoter regions to inhibit its *** ESCC tissues,c-Myc expression was inversely correlated with NS1-BP levels,and was associated with a shorter ***:Our findings highlight the role and importance of NS1-BP in radiosensitivity of *** the NS1-BP/c-Myc pathway may provide a novel therapeutic strategy for ESCC.

关键词： Esophageal squamous cell carcinoma NS1-BP Prognostic biomarker Radiotherapy c-Myc

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A Hessian Recovery Based Linear Finite Element Method for Molecular Beam Epitaxy Growth Model with Slope Selection

引用

Advances in Applied Mathematics and Mechanics 2024年第1期16卷 1-23页

作者： Minqiang Xu qingsong Zou College of Science Zhejiang University of TechnologyHangzhouZhejiang 310023China School of Computer Science and Engineering Sun Yat-Sen UniversityGuangzhouGuangdong 510275China School of Computer Science and Engineering and Guangdong Province Key Laboratory of Computational ScienceSun Yat-Sen UniversityGuangzhouGuangdong 510275China

In this paper,we present a Hessian recovery based linear finite element method to simulate the molecular beam epitaxy growth model with slope *** the time discretization,we apply a first-order convex splitting method and secondorder Crank-Nicolson *** the space discretization,we utilize the Hessian recovery operator to approximate second-order derivatives of a C^(0)linear finite element function and hence the weak formulation of the fourth-order differential operator can be discretized in the linear finite element *** energy-decay property of our proposed fully discrete schemes is rigorously *** robustness and the optimal-order convergence of the proposed algorithm are numerically *** a large spatial domain for a long period,we simulate coarsening dynamics,where 1/3-power-law is observed.

关键词： Molecular beam epitaxy Hessian recovery linear finite element method superconvergence.

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Design of an automated robotic microinjection system for batch injection of zebrafish embryos and larvae

引用

Microsystems & Nanoengineering 2024年第1期10卷 89-103页

作者： Zhongyi Guo Nana Ai Wei Ge qingsong Xu Department of Electromechanical Engineering Faculty of Science and TechnologyUniversity of MacaoMacaoChina Department of Biomedical Sciences and Centre of Reproduction Development and Aging(CRDA)Faculty of Health SciencesUniversity of MacaoMacaoChina

This paper presents the design of a vision-based automated robotic microinjection system for batch injection of both zebrafish embryos and larvae.A novel visual recognition algorithm based on an automatic threshold and excessive dilatation is introduced to accurately identify the center of zebrafish embryos and larval yolks.A corresponding software system is developed using the producer-consumer model as the framework structure,and a friendly user interface is designed to allow operators to choose from a range of desired functions according to their different *** addition,a novel microstructural agarose device is designed and fabricated to simultaneously immobilize mixed batches of embryos and ***,a prototype microinjection system is fabricated by integrating hardware devices with visual *** experimental study is conducted to verify the performance of the robotic microinjection *** results show that the reported system can accurately identify zebrafish embryos and larvae and efficiently complete batch microinjection tasks of the mixtures with an injection success rate of 92.05%in 13.88 s per *** with manual and existing microinjection systems,the proposed system demonstrates the merits of versatility,excellent efficiency,high success rate,high survival rate,and sufficient stability.

关键词： zebra automated hardware

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

局部晚期不可手术食管癌放射治疗研究进展

引用

中华肿瘤防治杂志 2023年第3期30卷 174-180页

作者：张天庞青松天津医科大学肿瘤医院放疗科国家恶性肿瘤临床医学研究中心天津市恶性肿瘤临床医学研究中心天津市肿瘤防治重点实验室天津300060

目的探讨局部晚期不可手术食管癌患者行根治性同步放化疗的研究进展。方法以“locally advanced esophageal cancer、radiotherapy”为英文关键词,“局部晚期食管癌、放疗”为中文关键词在PubMed和中国知网数据库进行检索,检索时间为... 详细信息

目的探讨局部晚期不可手术食管癌患者行根治性同步放化疗的研究进展。方法以“locally advanced esophageal cancer、radiotherapy”为英文关键词,“局部晚期食管癌、放疗”为中文关键词在PubMed和中国知网数据库进行检索,检索时间为自建库至2022年10月。共检索到英文文献1 668篇,中文文献138篇。纳入标准:(1)局部晚期食管癌的流行病学、放疗技术和剂量、放疗靶区范围、同步化疗方案以及新辅助放化疗;(2)放疗联合免疫检查点抑制剂在局部晚期食管癌治疗中的研究进展。排除标准:(1)综述类文献及个案报道;(2)重复的临床试验;(3)Ⅰ期临床试验。共纳入文献57篇(中文5篇,英文52篇)。结果局部晚期不可手术食管癌目前的主要治疗方式仍是根治性同步放化疗。放疗技术首选调强放射治疗(IMRT),放疗靶区采用累及野照射(IFI)。放疗剂量的提高和同步化疗方案的改变并未提高患者的治疗疗效。经过诱导放化疗后降期的患者也可能有手术机会,从而获得更好的生存获益。食管癌免疫治疗的相关临床试验正在进行,免疫治疗的添加有可能带来更好的生存获益。结论局部晚期不可手术食管癌的治疗需要成熟可靠的筛选模式,需针对每位患者制定个体化治疗方案。

关键词：食管癌放射治疗局部晚期不可手术

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：